IL-1β is a critical mediator of trained immunity and chronic inflammatory hepatopathies such as NASH and NAFLD, raising the question of the therapeutic targeting of the IL-1/IL-1R axis. This evidence concerns the gene IL1A and metabolic dysfunction-associated steatohepatitis.